Revive Biotechnology develops a targeted therapeutic approach for central retinal artery occlusion through intra-arterial drug delivery techniques. This treatment aims to restore retinal blood flow and prevent vision loss in patients affected by this condition.
Funding
$256K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Central retinal artery occlusion (CRAO) is a rare, acute condition that deprives the retina of oxygen, leading to rapid vision loss. Currently, there is no effective treatment for CRAO, leaving patients with permanent visual impairment. Blinding retinal diseases due to tissue hypoxia impact just under 1 million patients per year.
Solution
ReVive Biotechnology is developing RBT101, an innovative oxygen nano-delivery system, to improve oxygenation of hypoxic retinal tissue. The therapy is designed for targeted and immediate delivery of oxygen to the retina via intra-arterial administration. Pre-clinical studies have demonstrated the ability of RBT101 to preserve retinal tissue structure, leading to improved visual outcomes. ReVive Biotechnology is working through the regulatory pathway with the US Food and Drug Administration (FDA) and is poised to reach human trials.
Target Audience
The primary target audience includes ophthalmologists and interventional radiologists treating patients with central retinal artery occlusion and other ischemic retinopathies.
Features
- RBT101 utilizes a nanotechnology-based drug delivery system for targeted oxygen delivery.
- Designed to improve oxygenation of hypoxic retinal tissue in patients with CRAO.
- Pre-clinical data demonstrates preservation of retinal tissue structure and improved visual function.
- Potential application for branch retinal artery occlusion (BRAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), and ischemic optic neuropathy (ION).